Arcturus Therapeutics, Inc. is an RNA medicines company. Our versatile RNA therapeutics platform enables development of all types of RNA medicines including small interfering RNA (siRNA), messenger RNA (mRNA), antisense RNA, microRNA and gene editing therapeutics.
Our proprietary unlocked nucleomonomer agent (UNA) Oligomer™ technology can be used to target any gene in the human genome, as well the genes of other species, such as viruses, for therapeutic purposes.
Our patented Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR™) nanoparticle delivery system allows safe and efficient in vivo delivery of all RNA medicines.
We use our innovative technologies to develop RNA medicines that treat rare diseases. We also collaborate with industry leaders including Ultragenyx Pharmaceutical, Inc. to develop novel RNA therapeutics.
May 30, 2017
Arcturus Therapeutics to Receive Up to $3 Million from Cystic Fibrosis Foundation Therapeutics to Advance a Novel LUNAR-Formulated mRNA CFTR Therapeutic
August 23, 2017
Pictures by Ernst and Young (Finalists for the Entrepreneur Of The Year 2017 Award® in San Diego)
August 9, 2017
Arcturus Therapeutics in the list of Cystic Fibrosis Key Companies